12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ENMD-2076: Phase I started

EntreMed began a single-blind, dose-escalation, crossover, U.S. Phase I trial to evaluate 2 doses of ENMD-2076 in about 29 healthy volunteers. The study includes a food effect arm and is expected to satisfy FDA's requirement...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >